SG11201608441YA - Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect - Google Patents

Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect

Info

Publication number
SG11201608441YA
SG11201608441YA SG11201608441YA SG11201608441YA SG11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA
Authority
SG
Singapore
Prior art keywords
prevention
salt
treatment
pharmaceutical composition
composition containing
Prior art date
Application number
SG11201608441YA
Other languages
English (en)
Inventor
Takashi Mizutani
Chihoko Yoshimura
Hitomi Kondo
Makoto Kitade
Shuichi Ohkubo
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of SG11201608441YA publication Critical patent/SG11201608441YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201608441YA 2014-06-24 2015-06-24 Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect SG11201608441YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014129740 2014-06-24
JP2015024785 2015-02-10
PCT/JP2015/068218 WO2015199136A1 (ja) 2014-06-24 2015-06-24 新規ピロロピリミジン化合物又はその塩、及びこれを含有する医薬組成物、特にnae阻害作用に基づく腫瘍等の予防剤及び/又は治療剤

Publications (1)

Publication Number Publication Date
SG11201608441YA true SG11201608441YA (en) 2016-11-29

Family

ID=54938214

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201608441YA SG11201608441YA (en) 2014-06-24 2015-06-24 Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect

Country Status (21)

Country Link
US (2) US9963456B2 (https=)
EP (1) EP3103802B1 (https=)
JP (1) JP6192741B2 (https=)
KR (1) KR101947289B1 (https=)
CN (1) CN106661031B (https=)
AU (1) AU2015281155B9 (https=)
BR (1) BR112016025835B1 (https=)
CA (1) CA2946833C (https=)
DK (1) DK3103802T3 (https=)
ES (1) ES2656772T3 (https=)
HU (1) HUE037266T2 (https=)
MX (1) MX2016015015A (https=)
MY (1) MY183327A (https=)
NO (1) NO3103802T3 (https=)
PH (1) PH12016502130A1 (https=)
PL (1) PL3103802T3 (https=)
PT (1) PT3103802T (https=)
RU (1) RU2658008C2 (https=)
SG (1) SG11201608441YA (https=)
TW (1) TWI605048B (https=)
WO (1) WO2015199136A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI623316B (zh) * 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
WO2018085818A1 (en) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018085833A2 (en) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
WO2018089786A1 (en) * 2016-11-11 2018-05-17 Millennium Pharmaceuticals, Inc. Atg7 inhibitors and the uses thereof
WO2018110591A1 (ja) * 2016-12-13 2018-06-21 ヤマサ醤油株式会社 抗ウイルス活性を有する2'-デオキシ-7-デアザプリンヌクレオシド誘導体
JP7060694B2 (ja) * 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物
CN108822145B (zh) * 2018-06-11 2020-10-23 广东工业大学 一种磺酰胺类化合物及其制备方法和应用
CN108640945B (zh) * 2018-06-11 2020-10-23 广东工业大学 一种酰胺类化合物及其制备方法与应用
AU2019301697A1 (en) * 2018-07-13 2021-01-07 Il-2Rx, Inc. Compounds, compositions, methods, and uses for treating cancer and immunological disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1848718E (pt) * 2005-02-04 2012-10-11 Millennium Pharm Inc Inibidores de enzimas de activação e1
WO2007067559A2 (en) * 2005-12-06 2007-06-14 Regents Of The University Of Minnesota Antibacterial agents
KR101450535B1 (ko) 2006-02-02 2014-10-14 밀레니엄 파머슈티컬스 인코퍼레이티드 E1 활성화 효소의 억제제
JP2013541587A (ja) 2010-11-05 2013-11-14 ミレニアム ファーマシューティカルズ, インコーポレイテッド Nedd8活性化酵素阻害剤の投与
US9233964B2 (en) 2011-01-07 2016-01-12 Leo Pharma A/S Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof
EP2738873A4 (en) * 2011-07-29 2015-04-01 Kuang Chi Innovative Tech Ltd ARTIFICIAL COMPOSITE MATERIAL AND ANTENNA PRODUCED FROM ARTIFICIAL COMPOSITE MATERIAL
MY171055A (en) * 2012-01-19 2019-09-23 Taiho Pharmaceutical Co Ltd 3,5-disubstituted alkynylbenzene compound and salt thereof

Also Published As

Publication number Publication date
KR20170016510A (ko) 2017-02-13
US9963456B2 (en) 2018-05-08
US20180162864A1 (en) 2018-06-14
US10174040B2 (en) 2019-01-08
RU2658008C2 (ru) 2018-06-19
JP6192741B2 (ja) 2017-09-06
TW201625629A (zh) 2016-07-16
PH12016502130B1 (en) 2016-12-19
KR101947289B1 (ko) 2019-02-12
EP3103802B1 (en) 2017-11-08
PL3103802T3 (pl) 2018-02-28
PT3103802T (pt) 2017-12-11
AU2015281155A1 (en) 2016-11-03
HUE037266T2 (hu) 2018-08-28
WO2015199136A1 (ja) 2015-12-30
AU2015281155B9 (en) 2017-11-16
PH12016502130A1 (en) 2016-12-19
NO3103802T3 (https=) 2018-04-07
RU2016149319A3 (https=) 2018-06-18
CN106661031B (zh) 2019-07-23
CA2946833A1 (en) 2015-12-30
EP3103802A1 (en) 2016-12-14
JPWO2015199136A1 (ja) 2017-04-27
EP3103802A4 (en) 2017-03-08
BR112016025835A2 (https=) 2017-08-15
CN106661031A (zh) 2017-05-10
BR112016025835B1 (pt) 2022-09-20
MY183327A (en) 2021-02-18
TWI605048B (zh) 2017-11-11
US20170066772A1 (en) 2017-03-09
RU2016149319A (ru) 2018-06-18
MX2016015015A (es) 2017-02-27
CA2946833C (en) 2019-03-05
AU2015281155B2 (en) 2017-07-13
ES2656772T3 (es) 2018-02-28
DK3103802T3 (en) 2017-12-11

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, preparations and methods for treating the disease
SG11201608441YA (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
IL264156A (en) Compounds, preparations and methods for treating the disease
IL254722A0 (en) Indoleamine 3,2-dioxygenase inhibitors for cancer treatment
HUE073569T2 (hu) Vegyületek, azok sói és alkalmazásuk betegségek kezelésére
PL3065732T3 (pl) Związki, kompozycje i odpowiednie zastosowania do zapobiegania i/lub leczenia dyslipidemii
ZA201707951B (en) Amide compound and use thereof as agent for the treatment and prevention of diseases caused by rna- and/or dna-containing viruses, and concomitant diseases
IL263697A (en) Compounds, preparations and methods for the treatment and/or prevention of cancer
HK1243935A1 (zh) 有机化合物
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
IL263793A (en) Compounds and preparations for the treatment of cancer
EP3241551A4 (en) Pharmaceutical composition for treating cancer, containing lactate metal salt
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
IL275525A (en) A pharmaceutical preparation for the treatment of cancer
EP3148570A4 (en) Pharmaceutical composition for preventing or treating skin rash
EP3162803A4 (en) New compound for inhibiting binding between dx2 protein and p14/arf protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient
HK1243936A1 (zh) 有机化合物
EP3290051A4 (en) Pharmaceutical composition for treating and/or preventing cancer
PL3236961T3 (pl) Kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu złośliwego
EP3235808A4 (en) Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same
IL252487B (en) Arylalkylamine compounds for use in the prevention or treatment of cancer
EP3267992A4 (en) Hypoestoxide, derivatives, related compounds, and agonists thereof for treatment or prevention of neurodegenerative diseases
EP3219323B8 (en) Pharmaceutical composition for treatment and/or prevention of hepatitis c
HK1235391A1 (en) Inhibitors of creatine transport and uses thereof